Heavy Chain Antibodies for CD22 Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for B-cell disorders characterized by CD22 expression, such as diffuse large B cell lymphoma and autoimmune diseases, lack effective therapeutic options, with existing monoclonal antibodies and CAR-T therapies showing inconsistent clinical efficacy.
Innovation Solution
Development of heavy chain-only antibodies (UniAbs) with specific binding affinity to CD22, comprising unique CDR sequences, which can be used in pharmaceutical compositions to treat B-cell disorders, including bispecific formats for enhanced therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional monoclonal antibodies are used to target CD22, then therapeutic treatment can be provided, but clinical efficacy is inconsistent
Solution Approach 1:
The invention extracts and utilizes only the heavy chain portion of the antibody molecule, creating heavy chain-only antibodies that lack light chains. This simplification removes structural complexity while maintaining therapeutic function, as the heavy chain alone can bind to CD22 with sufficient affinity and efficacy for treating B-cell malignancies.
Solution Approach 2:
The invention changes the fundamental structural parameters of the antibody by eliminating the light chain component and modifying the heavy chain structure. This parameter change results in a more reliable therapeutic agent with consistent clinical efficacy, as the simplified heavy chain-only structure reduces variability in antibody behavior and improves reproducibility of therapeutic effects.
2Reliability
If standard monoclonal antibodies are used, then CD22 binding is achieved, but therapeutic consistency varies
Solution Approach 1:
The invention extracts the essential therapeutic function from the complete antibody structure by using only the heavy chain. This extraction eliminates the light chain variable region that contributes to structural complexity and potential variability, resulting in more consistent therapeutic behavior while maintaining CD22 binding capability.
Solution Approach 2:
The invention creates a composite therapeutic approach by combining the heavy chain variable region (for CD22 binding) with engineered constant regions and Fc portions. This composite structure provides both the specificity needed for consistent CD22 targeting and the effector functions required for reliable therapeutic outcomes, while reducing overall structural complexity compared to conventional antibodies.
3Device complexity
If conventional antibody structures are used, then light chain-hydrophobic interaction stabilizes the complex, but structural simplification is limited
Solution Approach 1:
The invention successfully removes the light chain component entirely, achieving maximum structural simplification. The heavy chain-only antibody maintains stability through engineered disulfide bonds, proper folding domains, and optimized constant region structures that compensate for the absence of light chain hydrophobic interactions.
Solution Approach 2:
The invention changes the stability parameters of the heavy chain by modifying amino acid sequences, introducing stabilizing mutations, and optimizing the constant region structure. These parameter changes allow the heavy chain to maintain structural integrity and functional stability without relying on light chain associations, enabling both simplification and stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The heavy chain-only antibodies demonstrate high affinity and specificity for CD22, offering potential for improved treatment outcomes in B-cell disorders by modulating CD22 biological activities and inducing targeted cell killing, with the ability to be engineered for cross-reactivity with other species.
Implementation Method 1
a heavy chain variable region that comprises: (a) a CDR1 having two or fewer substitutions in any of the amino acid sequences of SEQ ID NOs: 1 to 10; and/or (b) a CDR2 having two or fewer substitutions in any of the amino acid sequences of SEQ ID NOs: 11 to 17; and/or (c) a CDR3 having two or fewer substitutions in any of the amino acid sequences of SEQ ID NOs: 18 to 23
Data Source
AI summary
Anti-CD22 heavy chain antibodies (e.g., UniAbs™) are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat B cell disorders that are characterized by the expression of CD22.